HOME >> MEDICINE >> NEWS
EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Porter Novelli
27-Mar-2007


Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EVEREST data use tolvaptan published JAMA and featured ACC

(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 For those ... in person, the Mesothelioma Applied Research Foundation ... on Tuesday, March 3, starting at 9:30 AM. , ... no registration. The broadcast can be accessed through any ... http://www.curemeso.org/symposium . , The Symposium is a unique event ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
(Date:2/26/2015)... CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ ... that 15 abstracts of studies in its neuroscience ... presentation during the 67 th American Academy ... D.C. , from April 18-25. The accepted ... product, DUOPA, in addition to investigational treatments in ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and specialty ... consumers, employers and government health plans $23.3 billion ... by the Pharmaceutical Care Management Association (PCMA). ... offers one of the easiest ways to reduce ... Mark Merritt . "Policymakers should resist efforts to ...
Breaking Medicine Technology:AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
Cached News: